Debraj Shome, MD, FRCS, FACS, MBA
The Esthetic Clinics, India
Dr. Debraj Shome is a top Facial Plastic Surgeon, Cosmetic Surgeon and Oculoplastic Surgeon. Dr. Shome co-founded The Esthetic Clinics. The Esthetic Clinics are a group of top-class centers, based in Mumbai, Hyderabad, Kolkata & New Delhi, India and dedicated to the disciplines of aesthetic surgery and skin care of the body. Dr. Shome is a Surgeon super specialized in Facial Plastic Surgery, Oculoplastic Surgery & Cosmetic Surgery & is a consultant at Breach Candy Hospital; Saifee Hospital, Girgaon, Mumbai; Apollo Spectra Hospital, Chembur, Mumbai & SL Raheja Fortis Hospital, Mahim, Mumbai, India. Dr. Shome also runs a NGO called Debabrata Auro Foundation which plays a role in the upliftment of the downtrodden. Dr. Shome is the ex-Head of the Institute of Aesthetic Surgery, Apollo Hospitals, Hyderabad, India. Dr. Shome was Visiting Faculty to the Department of Head & Neck Surgery at MD Anderson Cancer Center, Houston, USA.
Introduction: Telogen Effluvium in a post Covid-19 patient causes excessive shedding of hair. Although it is a self-limiting type of hair loss, the psychological impact it causes is severe and no definite treatment is available till now. In the past studies, a novel biomimetic peptide hair growth formulation has shown promising results in various types of alopecia, both in men and women.
Aim: In this study we aim to establish efficacy of a novel biomimetic peptide hair growth formulation administration in Covid-19 induced persistent Telogen Effluvium for hair re-growth.
Materials and Methods: 20 adult patients (all females) presenting with persistent Telogen Effluvium starting few weeks after recovery from Covid-19 infection and continued beyond 6 months were included for the study.1.5 ml solution of a novel biomimetic peptide hair growth formulation was administered in the scalp per session. A total of 8 sessions (one session every four weeks) were done. The results were assessed at the baseline, 4thsession, and 1 month after 8th session.
Results: Most patients showed significant reduction in hair fall; 89% patients showed excellent hair growth. Global photographic assessment score showed marked improvement, which maintained even post therapy. Videomicroscopic assessment showed increase in the hair count (mean=29.32) after 8thsession, that further improved even post therapy. The subjective assessment scores for overall hair growth, appearance of hair, reduction in visibility of the scalp and hair loss were 4, 4.5, 4.25 and 5 respectively.
Conclusion; The Covid-19 stress induced persistent Telogen Effluvium can be daunting on the patients post Covid -19 as they are recovering from that stress, trauma and hospitalization. Management of Covid-19 induced persistent Telogen Effluvium has been unclear and futile so far. The present study suggests a definitive and quantifiable role of the novel biomimetic peptide hair growth formulation in the Covid-19 induced persistent Telogen Effluvium patients for significant improvement in hair density and hair count, and also reduces the hair fall.
Take Home Message
Management of Covid-19 induced persistent Telogen Effluvium has been unclear and futile so far. The present study suggests a definitive and quantifiable role of the novel biomimetic peptide hair growth formulation in the Covid-19 induced persistent Telogen Effluvium patients for significant improvement in hair density and hair count, and also reduce the hair fall.